Samuel Aaron Funt

Samuel Aaron Funt is an Assistant Professor in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK), specializing in Genitourinary Oncology. He serves as an Assistant Attending physician with primary affiliation to the Solid Tumor Oncology Division and Genitourinary Oncology Service. His clinical practice focuses on treating patients with germ cell tumors and urothelial carcinomas within one of the world's leading cancer treatment institutions.

Dr. Funt's research centers on genitourinary malignancies with particular emphasis on germ cell tumors and urothelial carcinomas. His work spans clinical outcomes research, predictive modeling of treatment response, quality of life assessments, and management of treatment-related toxicities. He has developed expertise in analyzing performance characteristics of predictive models for surgical pathology following chemotherapy, establishing baseline quality-of-life metrics for testicular cancer patients, and evaluating cutaneous toxicities associated with novel immunotherapy combinations. His research bridges clinical oncology with quantitative methods to improve decision-making for complex cancer cases.

Analysis of Dr. Funt's recent publications reveals a strong focus on improving clinical decision-making through data-driven approaches. His work demonstrates integration of patient-reported outcomes with traditional efficacy metrics, recognizing quality of life as critical to comprehensive cancer care. The research shows particular attention to predictive modeling for surgical pathology after chemotherapy, quality of life assessment in germ cell tumor patients, and documentation of toxicities with emerging immunotherapies like enfortumab vedotin and pembrolizumab combinations.

Dr. Funt maintains a robust collaborative network at MSK with extensive partnerships including Dr. Darren Feldman (47 collaborations), Dr. David Sheinfeld (23 collaborations), and Dr. George Bosl (21 collaborations). His work appears predominantly in the Journal of Clinical Oncology (72 publications), with additional contributions to Annals of Oncology, Clinical Cancer Research, and European Urology. His research program is well-integrated within the Solid Tumor Oncology Division, contributing to both clinical care protocols and scholarly advancement in genitourinary malignancies.